Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17995256 | 0.83 | MCL1 (0.61) | MCL1DAOMEN1KMT2ASLC9A1 | |
| SCHEMBL3635435 | 0.83 | MTNR1A (0.52) | MCL1DAOALDH1A1TSHRNOD2 | |
| SCHEMBL29524946 | 0.81 | NR1H2 (0.55) | NR1H2NR1H3CA12CA9NOD2 | |
| SCHEMBL387114 | 0.81 | MCL1 (0.43) | MCL1NR1H2DAOALDH1A1TSHR | |
| SCHEMBL4791517 | 0.79 | NOD2 (0.60) | MCL1ALDH1A1TSHRNOD2NOD1 | |
| SCHEMBL19410240 | 0.77 | KMT2A (0.52) | MCL1NR1H2ALDH1A1NOD2NOD1 | |
| SCHEMBL16264927 | 0.75 | CNR2 (0.54) | MCL1ALDH1A1NOD2NOD1MEN1 | |
| SCHEMBL319362 | 0.75 | CNR2 (0.52) | MCL1ALDH1A1NOD2NOD1MEN1 | |
| SCHEMBL2157437 | 0.75 | DAO (0.65) | MCL1DAOALDH1A1TSHRSLC9A1 | |
| SCHEMBL30396896 | 0.75 | DAO (0.65) | MCL1DAOALDH1A1TSHRSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264480-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2006-11-23 | — | — | US | disclosed |
| EP-1311477-A4 | NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2005-01-12 | — | — | EP | disclosed |
| US-20030203944-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-10-30 | — | — | US | disclosed |
| EP-1311477-A1 | NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016317-A1 | NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264480-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TRPV5 | MCL1 2687/4885NR1H2 1045/4885DAO 2185/4885 |
| US-20030203944-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TRPV5 | MCL1 2687/4885NR1H2 1045/4885DAO 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.